

Correction No. 1 made to the List of Medications on March 1, 2018

An Act respecting prescription drug insurance
(chapter A-29.01, s. 60, 7th par. and s. 60.2)

In accordance with 60.2 of the Act respecting prescription drug insurance, the Régie de l'assurance maladie du Québec was informed of the decrease in the price of several medications. Consequently, it has made the required corrections to the List of Medications, attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan (CQLR, chapter A-29.01, r. 3), which came into force on 1 March 2018.

These corrections follow the announcement by the Minister of Health and Social Services, dated 16 July 2017, that an agreement in principle had been concluded between the Québec government and the Canadian Generic Pharmaceutical Association. Subsequent to this agreement in principle and the resulting listing agreements with generic drug manufacturers, a decrease in the price of generics will apply effective from 3 April 2018. In addition, certain manufacturers have been asked to apply a price decrease effective also from 3 April 2018, this in line with the publication of the price decrease announced by the pan-Canadian Pharmaceutical Alliance.

The list of products and prices affected by the price is available on the website of the Régie, in the section "Produits touchés par la baisse de prix," at the following address: www.ramq.gouv.qc.ca/fr/professionnels/professionnels/Pages/liste-medicaments.aspx.

As well, the Régie was notified by the manufacturer Merck of the decrease in the price of the following medications, regarding which it has made the following corrections to the cost of their package size and unit price:

Code	Brand name	Manufacturer	Package size	Cost of package size indicated	Corrected cost of package size	Unit price indicated	Corrected unit price
02455323	Brenzys (syringe)	Merck	4	1076.00	1020,00 \$	296.0000	255.0000
02455331	Brenzys (pen)	Merck	4	1076.00	1020.00	296.0000	255.0000

These corrections were made due to the regulatory commitment by the manufacturer to submit to the Minister of Health and Social Services a selling price that is not higher than the selling price which it consented to other provincial prescription drug insurance programs for the same medication (best price in Canada).

These corrections have effect from 3 April 2018.

Publication of these corrections on the website of the Régie imparts authentic value to them, in accordance with the last paragraph of section 60 of the Act respecting prescription drug insurance.

Québec, 26 March 2018

Original signed by :

PAUL MARCEAU
President and Chief Executive Officer
Régie de l'assurance maladie du Québec